RxDoctor Payments Data

Jacqueline Mouton, PA

Physician Assistant · Cypress, TXNPI 1851558639

Payments from drug & device makers

$2,574in general payments, 2019–2025

Across 145 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$791
  • Exact Sciences$383
  • Boehringer Ingelheim$257
  • Pfizer$210
  • AstraZeneca$200
  • AbbVie$114
  • plus $619 from 20 others

What the payments were for

  • Food & beverage$2,574100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,574 in reported general payments places this provider in the 80th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$75,149
Medicare patients
392
Services billed
1,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$97,155
JardianceEmpagliflozin32$43,215
XareltoRivaroxaban27$30,167
EliquisApixaban13$20,791
JanuviaSitagliptin Phosphate14$17,987
TradjentaLinagliptin18$17,897
MounjaroTirzepatide12$12,535
Levothyroxine Sodium223$2,865
Rosuvastatin Calcium159$2,556
Atorvastatin Calcium269$2,528
Duloxetine Hcl56$2,195
Metoprolol Succinate137$2,154
Tamsulosin Hcl103$2,105
Amlodipine Besylate212$1,678
Azelastine Hcl55$1,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$791$97,15577 claims
Boehringer IngelheimJardiance, Tradjenta$257$61,11250 claims
Johnson & JohnsonXarelto$56$30,16727 claims
PfizerEliquis$210$20,79113 claims
MerckJanuvia$12$17,98714 claims
AbbVieSynthroid$114$1,14432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →